Table 2.
BsAbs that have been on the market.
| Company | Trade name | Common name | Time of approval | Target | Indication | |
|---|---|---|---|---|---|---|
| 1 | TrionPharma | Removab | Catumaxomab | 2009.4 | CD20×EpCAM | Malignant ascites |
| 2 | Amgen | Blincyto | Blinatumomab | 2014.12 | CD3×CD19 | ALL |
| 3 | Roche | Hemlibra | Emicizumab | 2017.11 | FIX×FX | Hemophilia A |
| 4 | Janssen | Rybrevant | Amivantamab | 2021.5 | EGFR×c-MET | NCSLC |
| 5 6 7 |
Genentech Roche Akeso |
Vabysmo Lunsumio - |
Faricimab Mosunetuzumab Candonilimab |
2022.1 2022.6 2022.6 |
VEGF×Ang-2 CD20×CD3 PD-1×CTLA-4 |
DME, w-AMD R/R FL R/M CC |